US 12,350,317 B2
Immunotherapy for the treatment and prevention of inflammatory bowel disease
Charles O. Elson, Birmingham, AL (US); Wayne Duck, Pell City, AL (US); Qing Zhao, Birmingham, AL (US); and Katie Alexander, Homewood, AL (US)
Assigned to THE UAB RESEARCH FOUNDATION, Birmingham, AL (US)
Appl. No. 17/426,234
Filed by THE UAB RESEARCH FOUNDATION, Birmingham, AL (US)
PCT Filed Feb. 7, 2020, PCT No. PCT/US2020/017319
§ 371(c)(1), (2) Date Jul. 28, 2021,
PCT Pub. No. WO2020/163782, PCT Pub. Date Aug. 13, 2020.
Claims priority of provisional application 62/802,873, filed on Feb. 8, 2019.
Prior Publication US 2022/0088145 A1, Mar. 24, 2022
Int. Cl. A61K 38/20 (2006.01); A61K 31/436 (2006.01); A61K 38/16 (2006.01); A61K 45/06 (2006.01); A61P 29/00 (2006.01)
CPC A61K 38/2013 (2013.01) [A61K 31/436 (2013.01); A61K 38/164 (2013.01); A61K 45/06 (2013.01); A61P 29/00 (2018.01)] 14 Claims
 
1. A method for treating or preventing inflammatory bowel disease comprising administering to a subject having inflammatory bowel disease or at risk of developing inflammatory bowel disease
a) an effective amount of a multi-epitope polypeptide comprising two or more flagellin T-cell receptor (TCR) epitopes selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 7 SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO; 27, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, and SEQ ID NO: 37; and
b) an effective amount of an agent that reduces flagellin antigen-specific memory T cells and/or increases regulatory T cells in the subject.